JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Clinical trial NCT06716658 · RECRUITING

Trial details

NCT number: NCT06716658
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, T-Cell NK-LGL Leukemia T-LGL Leukemia Cutaneous T Cell Lymphoma Cutaneous T Cell Lymphoma (CTCL)Large Granular Lymphocyte Leukemia Large Granular Lymphocytic Leukemia Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma Mycosis Fungoides

Start date: 2024-12-25
Primary completion: 2026-11-15
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.